Strategic Partnerships Opportunity to expand collaborations with philanthropic and gene therapy networks, as evidenced by the ongoing Anthony Nolan partnership to advance CORDStrom for recessive dystrophic epidermolysis bullosa, suggesting potential cross-disease and manufacturing collaboration avenues.

Cell Therapy Manufacturing Recent collaboration with CGT Catapult to develop commercial-scale manufacturing capabilities highlights a sales channel for process development, manufacturing services, and potential equipment or platform licensing for scalable cell therapy production.

Preclinical to Clinical Strong focus on immuno-oncology and NK cell–based approaches with INKmune and preclinical data on INB03 (XPro1595) to address resistance and metastasis, indicating demand for translational research services, biomarker development, and companion diagnostics.

Diversified Investor Signals Company has substantial funding ($145M) with modest revenue, signaling willingness to invest in partnerships that accelerate development and manufacturing readiness, presenting co-development or milestone-based deal structures as attractive options.

Industry Presence Active participation in major scientific forums (AACR, CTAD, Clinical Trials on Alzheimer’s) and public announcements create opportunities for sponsored talks, exhibit partnerships, and targeted outreach to researchers and potential strategic collaborators in oncology and beyond.